Wave Life Sciences to Present at Jefferies London Healthcare Conference
Wave Life Sciences (Nasdaq: WVE) has announced its participation in the Jefferies London Healthcare Conference. The company's President and CEO, Paul Bolno, MD, MBA, will engage in an analyst-led fireside chat on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET.
The presentation will be accessible through a live webcast in the 'Investor Events' section of Wave Life Sciences' website. A replay will be available for a time after the event.
Wave Life Sciences (Nasdaq: WVE) ha annunciato la sua partecipazione alla Jefferies London Healthcare Conference. Il Presidente e CEO dell'azienda, Paul Bolno, MD, MBA, parteciperà a un'intervista condotta da un analista mercoledì 20 novembre 2024, alle 16:30 GMT / 11:30 ET.
La presentazione sarà accessibile attraverso una diretta web nella sezione 'Eventi per Investitori' del sito di Wave Life Sciences. Una registrazione sarà disponibile per un periodo dopo l'evento.
Wave Life Sciences (Nasdaq: WVE) ha anunciado su participación en la Jefferies London Healthcare Conference. El Presidente y CEO de la compañía, Paul Bolno, MD, MBA, participará en una charla junto a un analista el miércoles 20 de noviembre de 2024, a las 16:30 GMT / 11:30 ET.
La presentación estará disponible a través de una transmisión en vivo en la sección 'Eventos para Inversores' del sitio web de Wave Life Sciences. Se podrá acceder a una repetición por un tiempo después del evento.
Wave Life Sciences (Nasdaq: WVE)가 Jefferies London Healthcare Conference에 참석한다고 발표했습니다. 회사의 사장 겸 CEO인 Paul Bolno, MD, MBA가 2024년 11월 20일 수요일 오후 4:30 GMT / 오전 11:30 ET에 애널리스트 주도 대화에 참여할 예정입니다.
발표는 Wave Life Sciences 웹사이트의 '투자자 이벤트' 섹션을 통해 생중계될 것입니다. 이벤트 후 일정 시간 동안 다시 시청할 수 있습니다.
Wave Life Sciences (Nasdaq: WVE) a annoncé sa participation à la Jefferies London Healthcare Conference. Le Président et CEO de l'entreprise, Paul Bolno, MD, MBA, participera à une discussion animée par un analyste le mercredi 20 novembre 2024, à 16h30 GMT / 11h30 ET.
La présentation sera accessible via une diffusion en direct dans la section 'Événements pour Investisseurs' du site de Wave Life Sciences. Un replay sera disponible pendant un certain temps après l'événement.
Wave Life Sciences (Nasdaq: WVE) hat seine Teilnahme an der Jefferies London Healthcare Conference angekündigt. Der Präsident und CEO des Unternehmens, Paul Bolno, MD, MBA, wird an einem von einem Analysten geleiteten Gespräch am Mittwoch, den 20. November 2024, um 16:30 Uhr GMT / 11:30 Uhr ET teilnehmen.
Die Präsentation wird über einen Live-Stream im Bereich 'Investor Events' der Website von Wave Life Sciences zugänglich sein. Eine Aufzeichnung wird eine Zeitlang nach der Veranstaltung verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET.
A live webcast of this presentation can be accessed by visiting “Investor Events” on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
FAQ
When is Wave Life Sciences (WVE) presenting at the Jefferies London Healthcare Conference 2024?
How can investors watch Wave Life Sciences' (WVE) presentation at the Jefferies Conference?
What type of presentation will Wave Life Sciences (WVE) give at the Jefferies Conference?